J7313 HCPCS Level II code: Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg
J7313 is the HCPCS code for “Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J7313Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg
Short description: Inj., iluvien, 0.01 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J7313 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2016
Where J7313 sits
- 1J codesDrugs administered other than orally
- 2Active code J7313Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J7313 mean?
J7313 is the HCPCS code for “Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J7313?
CMS lists J7313’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J7313
All J codesJ7307Etonogestrel (contraceptive) implant system, including implant and suppliesJ7308Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)J7309Methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gramJ7310Ganciclovir, 4.5 mg, long-acting implantJ7311Injection, fluocinolone acetonide, intravitreal implant (retisert), 0.01 mgJ7312Injection, dexamethasone, intravitreal implant, 0.1 mgJ7314Injection, fluocinolone acetonide, intravitreal implant (yutiq), 0.01 mgJ7315Mitomycin, ophthalmic, 0.2 mgJ7316Injection, ocriplasmin, 0.125 mgJ7318Hyaluronan or derivative, durolane, for intra-articular injection, 1 mgJ7320Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mgJ7321Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose